What’s Ahead for Theravance Biopharma, Inc. (TBPH) After Today’s Significant Decline?

Theravance Biopharma, Inc. (NASDAQ:TBPH) Logo

Investors sentiment decreased to 1.19 in 2019 Q2. Its down 0.73, from 1.92 in 2019Q1. It turned negative, as 12 investors sold Theravance Biopharma, Inc. shares while 20 reduced holdings. 10 funds opened positions while 28 raised stakes. 34.36 million shares or 3.09% more from 33.32 million shares in 2019Q1 were reported.
Barclays Public Ltd Co reported 110,239 shares. D E Shaw & reported 0% in Theravance Biopharma, Inc. (NASDAQ:TBPH). State Of New Jersey Common Pension Fund D reported 265,459 shares stake. 53,065 are held by Chicago Equity Prtnrs Lc. California Public Employees Retirement, a California-based fund reported 62,715 shares. Bancorporation Of Ny Mellon Corporation accumulated 207,843 shares. Citadel Llc invested in 17,403 shares. Nuveen Asset Management Ltd Com reported 221,092 shares. 18,830 were reported by Voya Mngmt Ltd Liability Corporation. Alliancebernstein Limited Partnership accumulated 62,935 shares or 0% of the stock. Swiss Commercial Bank holds 77,342 shares or 0% of its portfolio. King Wealth invested in 0.12% or 24,500 shares. Nomura Holding Incorporated owns 210,000 shares. Rock Springs Mngmt Lp stated it has 0.32% in Theravance Biopharma, Inc. (NASDAQ:TBPH). Zurcher Kantonalbank (Zurich Cantonalbank) reported 2,679 shares stake.

The stock of Theravance Biopharma, Inc. (NASDAQ:TBPH) is a huge mover today! The stock decreased 3.17% or $0.75 during the last trading session, reaching $22.92. About 185,043 shares traded. Theravance Biopharma, Inc. (NASDAQ:TBPH) has declined 10.59% since September 13, 2018 and is downtrending. It has underperformed by 10.59% the S&P500.
The move comes after 6 months negative chart setup for the $1.30 billion company. It was reported on Sep, 13 by Barchart.com. We have $21.77 PT which if reached, will make NASDAQ:TBPH worth $64.90M less.

Analysts await Theravance Biopharma, Inc. (NASDAQ:TBPH) to report earnings on November, 5. They expect $-1.04 EPS, up 5.45 % or $0.06 from last year’s $-1.1 per share. After $-0.72 actual EPS reported by Theravance Biopharma, Inc. for the previous quarter, Wall Street now forecasts 44.44 % negative EPS growth.

Theravance Biopharma, Inc. (NASDAQ:TBPH) Ratings Coverage

Among 2 analysts covering Theravance Biopharma (NASDAQ:TBPH), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Theravance Biopharma has $55 highest and $55 lowest target. $55’s average target is 139.97% above currents $22.92 stock price. Theravance Biopharma had 3 analyst reports since March 20, 2019 according to SRatingsIntel. Piper Jaffray maintained Theravance Biopharma, Inc. (NASDAQ:TBPH) rating on Wednesday, June 19. Piper Jaffray has “Buy” rating and $55 target. The company was maintained on Wednesday, March 20 by Cantor Fitzgerald.

More notable recent Theravance Biopharma, Inc. (NASDAQ:TBPH) news were published by: Finance.Yahoo.com which released: “Introducing Theravance Biopharma (NASDAQ:TBPH), The Stock That Slid 54% In The Last Five Years – Yahoo Finance” on June 17, 2019, also Nasdaq.com with their article: “Theravance Announces Positive Early Data on JAK Inhibitor – Nasdaq” published on September 10, 2019, Finance.Yahoo.com published: “Here’s What Hedge Funds Think About Theravance Biopharma Inc (TBPH) – Yahoo Finance” on May 02, 2019. More interesting news about Theravance Biopharma, Inc. (NASDAQ:TBPH) were released by: Finance.Yahoo.com and their article: “Read This Before Buying Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares – Yahoo Finance” published on April 24, 2019 as well as Nasdaq.com‘s news article titled: “Oversold Conditions For Theravance Biopharma (TBPH) – Nasdaq” with publication date: May 20, 2019.

Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company has market cap of $1.30 billion. The firm offers VIBATIV , a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria. It currently has negative earnings. The Company’s product candidates include TD-1792 that is in phase III clinical trials for the treatment of skin and soft tissues infections; TD-6450, a multivalent NS5A inhibitor, which is in Phase II study for Hepatitis C Virus; and Revefenacin (TD-4208), a long acting muscarinic antagonist that is in Phase III clinical studies for chronic obstructive pulmonary diseases.

Theravance Biopharma, Inc. (NASDAQ:TBPH) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.